Longhorn’s Universal Influenza Vaccine Candidate LHNVD-105 Shows Promising Strain Coverage

Published on :

Longhorn Vaccines & Diagnostics, LLC (Longhorn), a privately held biotechnology company, today announced publication of pre-clinical data on the company’s universal influenza vaccine candidate, LHNVD-105, which is a multi-epitope unconjugated influenza composite peptide formulated in collaboration with the U.S. Army’s Liposomal Adjuvant (ALFQ). The study, which appears in the June issue of the international, peer-reviewed journal Vaccines, suggests that LHNVD-105 provides broader coverage than seasonal vaccines currently on the market and is less costly to administer and manufacture.